Exact Sciences has announced promising initial data for its blood-based colon cancer test, potentially offering a new avenue for early detection. The company revealed the findings at the European Society for Medical Oncology conference in Barcelona, Spain.
Promising Initial Results
The study, involving over 3,000 samples, demonstrated that the blood test detected 88.3% of colon cancers, indicating strong sensitivity. Furthermore, the test exhibited a specificity of 90.1%, meaning it accurately returned a negative result for those without cancer. Notably, the test also identified 31.2% of advanced precancers, which are abnormal cell growths that can precede the development of the disease.
Implications for Colon Cancer Screening
These initial results suggest that Exact Sciences' blood test could become a competitive alternative to existing colon cancer screening methods. The current standard involves stool-based tests, which, while effective, can have limitations in patient compliance and acceptance. A blood-based test could offer a more convenient and less invasive option, potentially increasing screening rates and leading to earlier detection of colon cancer.
Ongoing Research and Future Plans
While these initial findings are encouraging, they are derived from a smaller study designed to help refine the test's algorithms and biomarkers. Exact Sciences is currently conducting a larger and more definitive study to further evaluate the test's performance. The company anticipates reporting the results of this trial in the first half of next year and subsequently plans to apply for Food and Drug Administration (FDA) approval.
Quote from Exact Sciences
"These initial results are a significant step forward in our efforts to develop a highly accurate and convenient blood-based test for colon cancer screening," said a spokesperson for Exact Sciences. "We are committed to advancing this technology and bringing it to market to improve patient outcomes."
